Calkins Daniel 4
4 · Verastem, Inc. · Filed May 20, 2025
Insider Transaction Report
Form 4
Verastem, Inc.VSTM
Calkins Daniel
Chief Financial Officer
Transactions
- Award
Common Stock
2025-05-16−38,850→ 125,198 total - Sale
Common Stock
2025-05-20$8.13/sh−11,143$90,593→ 114,055 total
Footnotes (2)
- [F1]The reported securities were subject to a performance RSU award that was granted on June 18, 2024. 150,000 RSUs vested on May 16, 2025, upon the Issuer's Compensation Committee of the board of directors determining the performance criteria of approval by the FDA of an NDA for the Company's combination therapy of avutometinib and defactinib for the treatment of low-grade serous ovarian cancer had occurred.
- [F2]The sale reported on this Form 4 represents shares sold by the Reporting Person to satisfy statutory withholding requirements in connection with the vesting of restricted stock units.